To date, two clinical trials of anti-TGF-β drugs in IPF have failed to show a significant clinical benefit (an anti-TGF-β antibody, and an oral integrin blocker; unpublished), while one oral agent (epigallocatechin-3-gallate) showed benefit in a single center study (52). The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.